Albert Labs International Corp.

Albert Labs International Corp. is a clinical research and laboratory-based drug development company serving the needs of mental health care. Through a succinct, real-world evidence (RWE)-driven clinical journey, Albert Labs seeks to commercialize its psychedelic-based treatments and, in doing so, bring psychedelic-assisted psychotherapy to patients sooner. Focused on accelerating access and faster approvals, Albert Labs prioritizes patients with urgent and unmet needs by developing licensed drugs to treat a variety of mental health conditions. Cancer-related distress, an original goal of Albert Labs' development program, is thought to affect more than 16 million patients worldwide.